• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

喉癌肿瘤浸润 CD8+ T 细胞与 PD-L1 表达的相关性及其预后意义:前瞻性非干预性试验。

Correlation Between Tumor Infiltration CD8+ T-cells And PD-L1 Expression In Laryngeal Cancer And Their Prognostic Significance: Prospective Non-interventional Trial.

机构信息

Clinical oncology department, faculty of medicine, Ain Shams university, Cairo, Egypt.

Pathology department, Faculty of Medicine, Ain Shams university, Cairo, Egypt.

出版信息

Gulf J Oncolog. 2021 Sep;1(37):23-31.

PMID:35152191
Abstract

INTRODUCTION

Tumor microenvironment plays crucial role in cancer evolution. There is a dynamic and continuous relation between immune cells and cancer cells' resistance. Tumor infiltration CD8-lymphocytes and programmed death ligand-1 have proved important prognostic role in different malignancies. We aimed at evaluating this role in laryngeal cancer.

PATIENTS AND METHODS

We prospectively analyzed laryngeal cancer patients' specimens, to identify the CD8-lymphocytes and the PD-L1 expression. A total score formed of the sum of percentage and intensity of PD-L1. A final rate was considered as negative or low when combined percentage and intensity scores 0 to 4, and high when scores 5-7. CD8-lymphocyte infiltration was divided into strong (= 10/100 of epithelial cells or =20/100 stromal cell infiltration) or weak (<10/100 epithelial cells or <20/100 stromal cell infiltration).

RESULTS

Forty patients were included; twelve had stage 1 or 2 and 28 with advanced stages. PD-L1 expressionwas positive in 92.5%. Neither the PD-L1 nor CD8- lymphocytes had overall survival impact, however high PD-L1 correlated with better survival in advanced stage subgroup (p = 0.036), high CD8-lymphocytes infiltration had better survival but did not reach significance. Therewas significant correlation between the CD8-lymphocyte infiltration; whether epithelial or stromal, and tumor PD-L1 expression; p-value of 0.001 and < 0.0001 respectively. Subgroup of patients with low CD8+ infiltration and low PD-L1 had the worst survival.

CONCLUSION

There is a correlation between CD8- l lymphocytes infiltration and PD-L1 expression inlaryngeal cancer and high PD-L1 expression is associated with better OS in advanced stages. Key words: PD-L1, CD8, laryngeal cancer, tumor microenvironment.

摘要

简介

肿瘤微环境在癌症演变中起着至关重要的作用。免疫细胞与癌细胞耐药性之间存在着动态的、连续的关系。肿瘤浸润 CD8-淋巴细胞和程序性死亡配体-1(PD-L1)已被证明在不同的恶性肿瘤中有重要的预后作用。我们旨在评估其在喉癌中的作用。

患者和方法

我们前瞻性分析了喉癌患者的标本,以确定 CD8-淋巴细胞和 PD-L1 的表达。一个由 PD-L1 的百分比和强度之和组成的总评分。当组合的百分比和强度评分 0 到 4 时,认为最终评分是阴性或低,当评分 5-7 时认为是高。CD8-淋巴细胞浸润分为强(=上皮细胞的 10/100 或=基质细胞的 20/100 浸润)或弱(<上皮细胞的 10/100 或<基质细胞的 20/100 浸润)。

结果

共纳入 40 例患者,其中 12 例为 1 期或 2 期,28 例为晚期。PD-L1 表达阳性率为 92.5%。PD-L1 和 CD8-淋巴细胞均与总生存无关,但在晚期亚组中,高 PD-L1 与更好的生存相关(p=0.036),高 CD8-淋巴细胞浸润有更好的生存,但无统计学意义。CD8-淋巴细胞浸润无论是上皮细胞还是基质细胞,与肿瘤 PD-L1 表达均有显著相关性;p 值分别为 0.001 和 <0.0001。低 CD8+浸润和低 PD-L1 患者亚组的生存最差。

结论

喉癌中 CD8-淋巴细胞浸润与 PD-L1 表达之间存在相关性,高 PD-L1 表达与晚期患者的 OS 相关。关键词:PD-L1、CD8、喉癌、肿瘤微环境。

相似文献

1
Correlation Between Tumor Infiltration CD8+ T-cells And PD-L1 Expression In Laryngeal Cancer And Their Prognostic Significance: Prospective Non-interventional Trial.喉癌肿瘤浸润 CD8+ T 细胞与 PD-L1 表达的相关性及其预后意义:前瞻性非干预性试验。
Gulf J Oncolog. 2021 Sep;1(37):23-31.
2
Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.三阴性乳腺癌中与程序性死亡配体1表达相关的肿瘤浸润淋巴细胞的多光谱定量免疫组织化学分析
Breast Cancer. 2020 Jul;27(4):519-526. doi: 10.1007/s12282-020-01110-2. Epub 2020 May 23.
3
Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.非小细胞肺癌患者中程序性细胞死亡配体-1(PD-L1)表达与CD8肿瘤浸润淋巴细胞密度的联合情况
J Egypt Natl Canc Inst. 2018 Dec;30(4):125-131. doi: 10.1016/j.jnci.2018.08.003. Epub 2018 Oct 15.
4
Prognostic value of tumor PD-L1 expression combined with CD8 tumor infiltrating lymphocytes in high grade serous ovarian cancer.肿瘤 PD-L1 表达联合 CD8 肿瘤浸润淋巴细胞对高级别浆液性卵巢癌的预后价值。
Int Immunopharmacol. 2017 Nov;52:7-14. doi: 10.1016/j.intimp.2017.08.017. Epub 2017 Aug 31.
5
Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.PD-L1表达和CD8 + T细胞浸润在肺神经内分泌肿瘤中的预后意义
Diagn Pathol. 2018 May 22;13(1):30. doi: 10.1186/s13000-018-0712-1.
6
Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration.程序性死亡配体 1 在喉癌中的表达及其对免疫细胞亚群浸润的影响。
Pathol Oncol Res. 2019 Oct;25(4):1437-1443. doi: 10.1007/s12253-018-0501-x. Epub 2018 Oct 25.
7
Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.程序性死亡配体 1 及其周围免疫状态对Ⅰ期肺癌的预后影响。
Clin Lung Cancer. 2020 Jul;21(4):e302-e314. doi: 10.1016/j.cllc.2020.01.013. Epub 2020 Jan 27.
8
Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.程序性死亡配体-1和肿瘤内CD8 + T淋巴细胞在卵巢癌肉瘤中的临床意义
PLoS One. 2017 Jan 26;12(1):e0170879. doi: 10.1371/journal.pone.0170879. eCollection 2017.
9
Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.PD-L1 和肿瘤浸润淋巴细胞在下咽鳞状细胞癌中的预后及临床病理意义。
Oral Oncol. 2020 Mar;102:104560. doi: 10.1016/j.oraloncology.2019.104560. Epub 2020 Jan 7.
10
PD-L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer.肿瘤微环境中 PD-L1+树突状细胞与结肠癌的良好预后和 CD8+T 细胞浸润相关。
Cancer Sci. 2021 Mar;112(3):1173-1183. doi: 10.1111/cas.14781. Epub 2021 Jan 21.

引用本文的文献

1
CD8 Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: A Review.头颈部癌中的 CD8 肿瘤浸润淋巴细胞:综述。
JCO Precis Oncol. 2024 Oct;8:e2400183. doi: 10.1200/PO.24.00183. Epub 2024 Nov 20.